Olema Pharmaceuticals’ (OLMA) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Olema Pharmaceuticals (NASDAQ:OLMA) in a research report sent to investors on Wednesday,Benzinga reports. HC Wainwright currently has a $30.00 target price on the stock. HC Wainwright also issued estimates for Olema Pharmaceuticals’ Q4 2024 earnings at ($0.64) EPS, FY2024 earnings at ($2.34) EPS, FY2025 earnings at ($2.82) EPS, FY2026 earnings at ($2.95) EPS, FY2027 earnings at ($2.83) EPS and FY2028 earnings at ($2.43) EPS.

Several other research analysts have also weighed in on the stock. Oppenheimer reiterated an “outperform” rating and set a $30.00 price objective on shares of Olema Pharmaceuticals in a report on Wednesday, August 7th. JPMorgan Chase & Co. cut their price target on shares of Olema Pharmaceuticals from $33.00 to $31.00 and set an “overweight” rating on the stock in a research note on Thursday, August 8th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $27.00.

Olema Pharmaceuticals Stock Down 9.2 %

Shares of Olema Pharmaceuticals stock opened at $9.17 on Wednesday. Olema Pharmaceuticals has a fifty-two week low of $8.51 and a fifty-two week high of $17.10. The business’s fifty day moving average is $12.00 and its two-hundred day moving average is $11.96. The firm has a market cap of $525.42 million, a PE ratio of -4.19 and a beta of 2.02.

Olema Pharmaceuticals (NASDAQ:OLMA) last released its earnings results on Tuesday, November 12th. The company reported ($0.60) EPS for the quarter, missing the consensus estimate of ($0.59) by ($0.01). Equities research analysts anticipate that Olema Pharmaceuticals will post -2.32 EPS for the current year.

Institutional Trading of Olema Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the business. Swiss National Bank lifted its stake in shares of Olema Pharmaceuticals by 8.8% during the first quarter. Swiss National Bank now owns 70,300 shares of the company’s stock worth $796,000 after purchasing an additional 5,700 shares in the last quarter. Susquehanna Fundamental Investments LLC purchased a new position in Olema Pharmaceuticals in the 1st quarter worth approximately $176,000. Entropy Technologies LP acquired a new stake in Olema Pharmaceuticals in the first quarter valued at approximately $161,000. EntryPoint Capital LLC raised its stake in shares of Olema Pharmaceuticals by 949.9% during the first quarter. EntryPoint Capital LLC now owns 14,530 shares of the company’s stock valued at $164,000 after purchasing an additional 13,146 shares during the period. Finally, Price T Rowe Associates Inc. MD lifted its position in shares of Olema Pharmaceuticals by 6.0% during the first quarter. Price T Rowe Associates Inc. MD now owns 26,251 shares of the company’s stock worth $298,000 after purchasing an additional 1,486 shares in the last quarter. 91.78% of the stock is owned by hedge funds and other institutional investors.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.